GRI Bio Announces Publication of Positive Preclinical Data from Lead Program GRI-0621 in the American Journal of Respiratory and Critical Care Medicine [Yahoo! Finance]
GRI Bio, Inc. (GRI)
Company Research
Source: Yahoo! Finance
Compared to controls, mice treated with GRI-0621 showed histological improvement in fibrotic lesion in the lung; Inhibition of iNKT activity led to a decrease in fibrosis score and total lung inflammation Company advancing Phase 2a biomarker study of GRI-0621 in patients with IPF with interim data expected Q3 2024 and topline data in Q4 2024 LA JOLLA, CA, July 02, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced the publication of positive preclinical data demonstrating its lead program GRI-0621 reduces the important inflammatory and fibrotic drivers in Idiopathic Pulmonary Fibrosis (IPF). The manuscript titled, “ Type 1 invariant natural killer T cells drive lung fibrosis ,” has been published in the American Journal of Respiratory and Critical Care Medicine. “Th
Show less
Read more
Impact Snapshot
Event Time:
GRI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GRI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GRI alerts
High impacting GRI Bio, Inc. news events
Weekly update
A roundup of the hottest topics
GRI
News
- GRI Bio Announces Publication of Positive Preclinical Data from Lead Program GRI-0621 in the American Journal of Respiratory and Critical Care MedicineGlobeNewswire
- GRI Bio to Present at the 8th Annual IPF SummitGlobeNewswire
- GRI Bio Announces Closing of $4.0 Million Public Offering [Yahoo! Finance]Yahoo! Finance
- GRI Bio Announces Closing of $4.0 Million Public OfferingGlobeNewswire
- GRI Bio Announces Korea Patent Granted for Proprietary Natural Killer T (NKT) Cell Modulators [Yahoo! Finance]Yahoo! Finance
GRI
Sec Filings
- 6/27/24 - Form 424B4
- 6/27/24 - Form 8-K
- 6/27/24 - Form EFFECT
- GRI's page on the SEC website